Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma by Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman

Get full text

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials by Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross

Get full text

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context by Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason A. Chesney, Kate Liu, Cheng-Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert

Get full text

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study by Gregory A Daniels, Sigrun Hallmeyer, Mark Grose, Jon Richards, Mark Faries, Brendan D Curti, Kim A Margolin, Yiwei Zhang, Lynn Feun, Anlong Li, John R Hyngstrom, Robert H I Andtbacka

Get full text

SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide... by Lei L Chen, Jing Zhu, Jonathan Schumacher, Chongjuan Wei, Latha Ramdas, Victor G Prieto, Arnie Jimenez, Marco A Velasco, Sheryl R Tripp, Robert H I Andtbacka, Launce Gouw, George M Rodgers, Liansheng Zhang, Benjamin K Chan, Pamela B Cassidy, Robert S Benjamin, Sancy A Leachman, Marsha L Frazier

Get full text